Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on therapies to treat central nervous system (CNS) disorders, and Catalent, have entered into a long-term commercial supply agreement for Roluperidone (MIN-101), Minerva’s investigational compound for the treatment of negative symptoms of schizophrenia. Catalent will manufacture and package the finished dose form of the drug at its facility in Schorndorf, Germany. Minerva is currently conducting a pivotal Phase III ...